OTHER × Leukemia, Lymphocytic, Chronic, B-Cell × ibritumomab tiuxetan × Clear all Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
Phase 2 Completed
20 enrolled 9 charts
Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Phase 1 Completed
20 enrolled
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2 Completed
42 enrolled 11 charts
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
Phase 2 Terminated
12 enrolled 7 charts
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma
Phase 1 Completed
12 enrolled
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
Phase 1/2 Completed
38 enrolled 8 charts
Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2 Completed
23 enrolled
Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1 Terminated
18 enrolled
Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1 Completed
44 enrolled